

WEST Search History

DATE: Wednesday, October 01, 2003

Set Name Query
side by side


Hit Count Set Name
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ

L8	((angiotensin) same (transdermal or transdermally))	87	L8
L7	((angiotensin antagonist) same (transdermal or transdermally))	0	L7
L6	((angiotensin adj antagonist) same (transdermal or transdermally))	0	L6
L5	((angiotensin II antagonist) same (transdermal or transdermally or topical or topically))	42	L5
L4	strungmann.inv.	4	L4
L3	(candesartan and transdermal)	114	L3
L2	(candesartan and (transdermal or topically or topical))	155	L2
L1	(candesartan same (transdermal or topically or topical))	2	L1

END OF SEARCH HISTORY

BEST AVAILABLE COPY



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Bo
Search	PubMed	for					Go	Clear
Limits		Preview/Index		History		Clipboard		Details
Display	Abstract	Show: 20	Sort	Send to	Text			

☐ 1: Blood Press Suppl 1994;5:38-42[Related Articles, Links](#)

Entrez PubMed

Topical application of AT1 receptor antagonists prevents medial and neointimal proliferation after balloon injury.

Taguchi J, Abe J, Ohno M, Schwartz SM, Kurokawa K.

PubMed Services

First Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

Related Resources


BEST AVAILABLE COPY

Angiotensin II plays an important role in neointima formation after vascular injury. A rat model of carotid artery injury was used i) to investigate the effect of single topical application of angiotensin II subtype 1 (AT1) receptor antagonists (CV11974, DuP753) in suppressing medial proliferation at day 2 and neointimal proliferation at day 14, and ii) to investigate the antiproliferative effects of additional application of L-arginine (a nitric oxide precursor). Drugs mixed in 25% (W/W) solutions of F127 pluronic gel were applied topically to injured vessels. Early medial proliferation of smooth muscle cells, assessed by the S-bromo-2'-deoxyuridine labelling index, was significantly suppressed by application of CV11974 (5 mg/kg), 7.5% +/- 2.2% vs. 19% +/- 3.9% in the control group. The intima/media ratio following CV11974 (10 mg/kg) or DuP753 (12.5 mg/kg) at day 14 was significantly lower than that in the control group (42% +/- 7%, 43% +/- 14%, and 123% +/- 11%, respectively). Additional application of L-arginine seemed to increase effectiveness, but was not statistically significant. In conclusion, single topical application of AT1 receptor antagonists was effective in suppressing early medial proliferation and neointima formation after balloon injury, suggesting that they may be clinically useful after angioplasty or vascular surgery.

PMID: 7889199 [PubMed - indexed for MEDLINE]

Display	Abstract	Show: 20	Sort	Send to	Text
---------	----------	----------	------	---------	------

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Bo	
Search	PubMed	▼	for					Go	Clear
		Limits	Preview/Index	History	Clipboard	Details			

Display	Abstract	▼	Show:	20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	-------	----	---	------	---	---------	------	---

☐ 1: Int Arch Allergy Immunol 2002 Sep;129(1):86-92 [Related Articles, Links](#)

Entrez PubMed



Effect of intranasal administration of CV-11974, a type 1 angiotensin II receptor antagonist, on airway hyperresponsiveness and airway inflammation induced by antigen inhalation in guinea pigs.

PubMed Services

Myou S, Fujimura M, Kita T, Watanabe K, Hirose T, Tachibana H, Ishiura Y, Nakao S.

Third Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa, Japan. myous@nifty.com

Related Resources

BEST AVAILABLE COPY

BACKGROUND: Angiotensin II is a putative mediator in asthma, but the effect of topical administration of type 1 angiotensin II (AT1) receptor antagonists on allergic airway reactions is not known. **OBJECTIVE:** To investigate the effect of intranasal administration of CV-11974, an AT1 receptor antagonist, and of PD123319, a type 2 angiotensin II (AT2) receptor antagonist, on antigen-induced airway reactions in guinea pigs. **METHODS:** Thirty minutes after intranasal topical administration of CV-11974 (0.1 or 1.0 mg/ml) or PD123319 (10 mg/ml) into the airways, the animals were given an antigen challenge. Airway hyperresponsiveness and bronchoalveolar lavage fluid were analyzed 24 h after the antigen challenge. **RESULTS:** Although these compounds did not inhibit antigen-induced early-phase bronchoconstriction or late-phase airway eosinophilia, intranasal administration of CV-11974 (but not PD123319) inhibited antigen-induced airway hyperresponsiveness in a dose-dependent manner 24 h after the antigen challenge. **CONCLUSION:** Intranasal administration of an AT1 receptor antagonist reduces antigen-induced airway hyperresponsiveness. Copyright 2002 S. Karger AG, Basel

PMID: 12373002 [PubMed - indexed for MEDLINE]

Display	Abstract	▼	Show:	20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	-------	----	---	------	---	---------	------	---